Results
For IC responders, IC+CCRT compared to IC+RT improved the locoregional
relapse-free survival (LRPFS) (median: 39.3 vs.15.13 months;P= 0.033), distant metastasis-free survival (DMFS) (median: 21.37
vs. 13.6 months; P= 0.044), PFS (median: 27.87 vs.11.37 months;P =0.048) and the overall survival (OS) (median: 39.33 vs. 18.03
months, P =0.027). A multivariate analysis confirmed IC+CCRT was a
positive prognostic factor for LRPFS and OS. However, for either all
patients or IC non-responders, IC+CCRT did not improve the survival
compared to
IC+RT.
Regarding acute toxicity, toxicities except ≥2 leucopenia were not
statistically different between the two groups.